Dr. Devlin’s research interests are in the development of adaptive and nonparametric regression methods for cancer research. With colleagues at Memorial Sloan Kettering, he recently developed a novel algorithm to refine and improve the discriminatory ability of an existing prognostic classifier by incorporating new genomic markers for censored survival data. His current research interests also include developing risk scores for high dimensional survival data when multiple markers may predict treatment response. Dr. Devlin collaborates with researchers in the Leukemia, Bone Marrow Transplant, and Myeloma Services in the design and analysis of retrospective and prospective studies.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Sean Devlin discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.